LUNDBECK ANNOUNCES POSITIVE PHASE 2 LONG-TERM DATA FOR BEXICASERIN IN RARE CHILDHOOD-ONSET EPILEPSIES, AT AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

Reuters · 1d ago

Please log in to view news